As U.S. firms scrap diversity targets, the CEO behind Ozempic and Wegovy took a pay cut for missing them
Novo Nordisk's CEO took a $1.5 million pay cut in 2024 as the pharma giant's share price tanked and it missed profit and DEI targets.
Novo Nordisk's CEO took a $1.5 million pay cut in 2024 as the pharma giant's share price tanked and it missed profit and DEI targets. Read More
